JP2015521465A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521465A5
JP2015521465A5 JP2015516684A JP2015516684A JP2015521465A5 JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5 JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid molecule
seq
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521465A (ja
JP6473416B2 (ja
Filing date
Publication date
Priority claimed from GBGB1210357.8A external-priority patent/GB201210357D0/en
Application filed filed Critical
Publication of JP2015521465A publication Critical patent/JP2015521465A/ja
Publication of JP2015521465A5 publication Critical patent/JP2015521465A5/ja
Application granted granted Critical
Publication of JP6473416B2 publication Critical patent/JP6473416B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516684A 2012-06-12 2013-06-12 第viii因子配列 Expired - Fee Related JP6473416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1210357.8 2012-06-12
GBGB1210357.8A GB201210357D0 (en) 2012-06-12 2012-06-12 Factor VIII sequences
PCT/GB2013/051551 WO2013186563A2 (en) 2012-06-12 2013-06-12 Factor viii sequences

Publications (3)

Publication Number Publication Date
JP2015521465A JP2015521465A (ja) 2015-07-30
JP2015521465A5 true JP2015521465A5 (enExample) 2016-08-04
JP6473416B2 JP6473416B2 (ja) 2019-02-20

Family

ID=46605791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516684A Expired - Fee Related JP6473416B2 (ja) 2012-06-12 2013-06-12 第viii因子配列

Country Status (8)

Country Link
US (6) US9447168B2 (enExample)
EP (1) EP2859016B1 (enExample)
JP (1) JP6473416B2 (enExample)
AU (1) AU2013276247B2 (enExample)
CA (1) CA2875449A1 (enExample)
ES (1) ES2640586T3 (enExample)
GB (1) GB201210357D0 (enExample)
WO (1) WO2013186563A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
EP3757116A1 (en) 2013-12-09 2020-12-30 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
US10058624B2 (en) * 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
MA42934A (fr) 2015-09-24 2018-08-01 Biomarin Pharm Inc Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci
CN116949052A (zh) * 2015-11-13 2023-10-27 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
EA036944B1 (ru) 2015-11-13 2021-01-19 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
EP3794112A1 (en) 2018-05-14 2021-03-24 BioMarin Pharmaceutical Inc. Stable expression of aav vectors in juvenile subjects
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
AU2020221340A1 (en) * 2019-02-15 2021-09-16 Bayer Healthcare Llc Gene editing for hemophilia A with improved Factor VIII expression
CN113710284A (zh) * 2019-06-05 2021-11-26 克里斯珀医疗股份公司 具有改善的因子viii表达的血友病a基因编辑
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
WO2022094461A1 (en) 2020-11-02 2022-05-05 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
CN119233998A (zh) * 2022-07-07 2024-12-31 深圳新诺微环生物科技有限公司 一种连接肽、包含连接肽的凝血八因子蛋白或其变体及其用途
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO2000011149A1 (en) 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US20090017533A1 (en) 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
EP1460131A3 (en) * 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
DK1804839T3 (da) 2004-09-22 2012-04-10 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007084487A2 (en) 2006-01-13 2007-07-26 Wayne State University Pericytes for use as stem cells
ES2535877T3 (es) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
US8512981B2 (en) 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
KR101597695B1 (ko) 2007-07-26 2016-02-25 유니큐어 아이피 비.브이. 차등 코돈 바이어스를 갖는 반복 암호 서열을 포함하는 배큘로바이러스 벡터
WO2009017533A1 (en) 2007-07-27 2009-02-05 Porteon Electric Vehicles, Inc. Modular light vehicle chassis
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011139629A2 (en) * 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
EP3044231B1 (en) 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii

Similar Documents

Publication Publication Date Title
JP2015521465A5 (enExample)
JP2020518268A5 (enExample)
JP2011101646A5 (enExample)
JP2022137029A (ja) CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用
JP2017532966A5 (enExample)
JP2013509168A5 (enExample)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
RU2019111648A (ru) Средство лечения болезни гентингтона на основе aav
JP2014012022A5 (enExample)
JP2017536116A5 (enExample)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2018534950A5 (enExample)
JP2020508685A5 (enExample)
JP2018138049A5 (enExample)
JP2018108113A5 (enExample)
JP2018520997A5 (enExample)
WO2013186563A3 (en) Factor viii sequences
JP2013027391A5 (enExample)
FI3851537T3 (fi) Hyperbilirubinemian hoito
RU2017126975A (ru) Модифицированные посттранскрипционные регуляторные элементы вирусов гепатита
JP2010516252A5 (enExample)
CN107427557A (zh) 用于包装和表达变体因子viii以治疗血友病的改良表达组件
RU2017142006A (ru) Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов
RU2018123181A (ru) Synp161, промотор для специфической экспрессии генов в палочковых фоторецепторах
JP2014514921A5 (enExample)